1/1
Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors
dataset
posted on 2015-11-03, 00:00 authored by Marco Redaelli, Susi Barollo, Caterina Mian, Corrado Betterle, Maurizio Iacobone, Ambrogio Fassina, Franco Mantero, Beatrice Rubin, Halenya Monticelli, Carla Mucignat, Loris Bertazza, Marco Boscaro, Raffaele PezzaniMitogen-activated protein kinase (MAPK) pathway is often deregulated in adrenocortical tumors (ACT) but with no concrete data confirming alteration rate. The objective of this study was to evaluate genetic alterations in key components of MAPK pathway. We found one BRAF mutation (p.V600E) and four HRAS silent mutations. No alteration was found in NRAS, KRAS, EGFR genes. The patient carrying BRAF mutation was further characterized by investigating his biomolecular and clinico-pathological findings. Therefore, even if MAPK signaling is activated in ACT, our results suggest that genetic alterations do not seem to represent a frequent mechanism of ACT tumorigenesis.
